VEGF-Apolymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration

2013 ◽  
Vol 14 (6) ◽  
pp. 623-630 ◽  
Author(s):  
Stefano Lazzeri ◽  
Michele Figus ◽  
Paola Orlandi ◽  
Anna Fioravanti ◽  
Teresa Di Desidero ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Functional Response ◽  
Age Related Macular Degeneration ◽  
Short Term ◽  
Intravitreal Ranibizumab ◽  
Age Related

IL-8andVEGFR-2polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration

2016 ◽  
Vol 17 (1) ◽  
pp. 35-9 ◽  
Author(s):  
Stefano Lazzeri ◽  
Paola Orlandi ◽  
Paolo Piaggi ◽  
Maria Sole Sartini ◽  
Giamberto Casini ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Functional Response ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related

scholarly journals Subthreshold laser treatment for reticular pseudodrusen secondary to age-related macular degeneration

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Giuseppe Querques ◽  
Riccardo Sacconi ◽  
Francesco Gelormini ◽  
Enrico Borrelli ◽  
Francesco Prascina ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Laser Treatment ◽  
Age Related Macular Degeneration ◽  
Short Term ◽  
Treated Area ◽  
Reticular Pseudodrusen ◽  
End Point ◽  
Age Related ◽  
Subthreshold Laser

AbstractThere is a lack of treatment aimed at the regression of reticular pseudodrusen (RPD) secondary to age-related macular degeneration (AMD). The aim of this prospective, pilot study is to evaluate the safety and short-term efficacy of subthreshold laser treatment (SLT) in patients affected by RPD secondary to dry AMD (dAMD). Twenty eyes of 20 patients (mean age 78.4 ± 6.8 years) with RPD secondary to dAMD were prospectively enrolled. All patients were treated in an extrafoveal area of 1.27 mm2 using end-point management yellow subthreshold laser and followed for 3 months. Best-corrected visual acuity was 0.140 ± 0.09 LogMAR at the baseline and no changes were observed during the follow-up (p = 0.232). No significant worsening was disclosed before and after the treatment analyzing the macular sensitivity of the treated area (p = 0.152). No topical and/or systemic side effects were disclosed during the 3-month follow-up. The distribution among the RPD stages changed after the treatment (p < 0.001). In detail, in the treated area, we observed a significant increase in the number of Stage 1 RPD during the follow-up (p = 0.002), associated with a significant decrease of Stage 3 RPD (p = 0.020). Outer nuclear layer (ONL) thickness analysis showed a significant increase after the treatment associated with RPD regression (p = 0.001). End-point management SLT appears a safe treatment for RPD secondary to dAMD, showing short-term safety outcomes. Our results suggest that SLT could be effective in inducing a RPD regression in terms of RPD stage and ONL thickening.

Can Intravitreal Ranibizumab Alter Retrobulbar Circulation in Eyes with Age-Related Macular Degeneration?

2013 ◽  
Vol 29 (8) ◽  
pp. 723-727 ◽  
Author(s):  
Kemal Yuksel ◽  
Hasan Altinkaynak ◽  
Adnan Kina ◽  
Necip Kara ◽  
Ahmet Taylan Yazici ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related

scholarly journals Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration [Corrigendum]

2016 ◽  
pp. 775
Author(s):  
Katarzyna Michalska-Malecka ◽  
Adam Kabiesz ◽  
Małgorzata Kimsa ◽  
Barbara Strzałka-Mrozik ◽  
Maria Formińska-Kapuścik ◽  
...  
Keyword(s):  
Gene Expression ◽  
Macular Degeneration ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document